NCT00645424View on ClinicalTrials.gov

A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol

PHASE4CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

October 31, 2004

Conditions
Hyperlipidemias
Interventions
DRUG

atorvastatin

Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks

DRUG

atorvastatin

Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks

DRUG

atorvastatin

Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks

Trial Locations (5)

Unknown

Pfizer Investigational Site, Kaohsiung City

Pfizer Investigational Site, Kaohsiung Hsien

Pfizer Investigational Site, Taichung

Pfizer Investigational Site, Taipei

Pfizer Investigational Site, Taoyuan Hsien

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00645424 - A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol | Biotech Hunter | Biotech Hunter